Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung DiseaseBusiness Wire • 12/30/20
Arcturus Reports Results From Early-Stage Testing of Its Coronavirus VaccineThe Motley Fool • 12/29/20
Arcturus Therapeutics plummets 53% after analyst downgrades following COVID-19 vaccine trial updates (ARCT)Business Insider • 12/29/20
Arcturus Therapeutics shares slide 37% in premarket after COVID vaccine data are deemed ‘underwhelming'Market Watch • 12/29/20
Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical DataBusiness Wire • 12/28/20
3 COVID-19 Vaccine Stocks That Could Be the Biggest Winners in a Post-Pandemic WorldThe Motley Fool • 12/16/20
Why You Might Want to Buy This Potentially Game-Changing COVID Vaccine Stock Right NowThe Motley Fool • 12/10/20
Why Shares of iBio, Marinus Pharmaceuticals, and Arcturus Therapeutics All Crashed on TuesdayThe Motley Fool • 12/08/20
Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common StockBusiness Wire • 12/08/20
Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) DeficiencyBusiness Wire • 12/07/20
3 mRNA Coronavirus Vaccine Stocks to Check Out That Aren't Pfizer, BioNTech, or ModernaThe Motley Fool • 11/17/20